Janet Mckeown

Sydney, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Seasonal variation in immune-related adverse events in advanced cancer patients.

Seasonal variation in immune-related adverse events in advanced cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: March 20, 2026

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Journal: JCO precision oncology

Published: March 12, 2026

Uptake of sentinel lymph node biopsy following a melanoma diagnosis: an Australian population-based study.

Uptake of sentinel lymph node biopsy following a melanoma diagnosis: an Australian population-based study.

Journal: Surgical oncology

Published: December 14, 2025

Timing of Definitive Surgical Management of Primary Cutaneous Melanoma: Association With Survival.

Timing of Definitive Surgical Management of Primary Cutaneous Melanoma: Association With Survival.

Journal: ANZ journal of surgery

Published: September 24, 2025

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2024

Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia.

Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia.

Journal: JAAD international

Published: August 10, 2024

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 02, 2024

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

Journal: Journal for immunotherapy of cancer

Published: January 15, 2024

Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 20, 2023

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 22, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026